To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
PE-backed SERB to buy BTG’s specialty pharma business for $800m
Boston Scientific Corporation has agreed to sell BTG's specialty pharmaceuticals business for $800 million.
